

# Robert Å eparoviÄ

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4312010/publications.pdf>

Version: 2024-02-01

34  
papers

606  
citations

1307594

7  
h-index

713466

21  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1140  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
2	Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma. <i>Oncology</i> , 2003, 64, 443-449.	1.9	33
3	Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer. <i>Tumori</i> , 2008, 94, 838-844.	1.1	21
4	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	5.0	17
5	Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study. <i>Croatian Medical Journal</i> , 2011, 52, 171-177.	0.7	16
6	Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. <i>Tumori</i> , 2008, 94, 838-44.	1.1	10
7	Unusual features of metastatic atypical carcinoid of the larynx. <i>European Archives of Oto-Rhino-Laryngology</i> , 1998, 255, 318-321.	1.6	8
8	Characteristics and Prognosis of Triple-Negative Breast Cancer Patients: a Croatian Single Institution Retrospective Cohort Study. <i>Acta Clinica Croatica</i> , 2020, 59, 97-108.	0.2	8
9	Parachordoma: A Case Report. <i>Tumori</i> , 2001, 87, 207-210.	1.1	7
10	Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA).. <i>Journal of Clinical Oncology</i> , 2011, 29, TPS118-TPS118.	1.6	7
11	Difference in Estimation of Side Effects of Chemotherapy between Physicians and Patients with Early-Stage Breast Cancer: The Use of Patient Reported Outcomes (PROs) in the Evaluation of Toxicity in Everyday Clinical Practice. <i>Cancers</i> , 2021, 13, 5922.	3.7	5
12	Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	1.3	4
13	Prognostic value of prominent DCIS component in the breast-conserving therapy of stage I and II invasive ductal breast cancer. <i>Breast</i> , 1999, 8, 72-76.	2.2	3
14	Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer. <i>Scientific Reports</i> , 2021, 11, 14395.	3.3	3
15	Rapid hair depigmentation in patient treated with pazopanib. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224209.	0.5	2
16	Uncommon Side Effects of Sunitinib Therapy in a Patient with Metastatic Renal Cell Cancer: Case Report. <i>Acta Clinica Croatica</i> , 2018, 57, 577-580.	0.2	2
17	The Role of Salivary and Serum Ca125 and Routine Blood Tests in Patients with Ovarian Malignancies. <i>Acta Clinica Croatica</i> , 2021, 60, 55-62.	0.2	2
18	Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. <i>Pathology and Oncology Research</i> , 2021, 27, 1609963.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.. Journal of Clinical Oncology, 2018, 36, 524-524.	1.6	2
20	Oxaliplatin Induced Pulmonary Fibrosis: A Case Report. Acta Clinica Croatica, 2020, 59, 761-764.	0.2	2
21	0134 CARIATIDE study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor (AI) medication for postmenopausal women with hormone sensitive early breast cancer. Breast, 2009, 18, S52.	2.2	1
22	1055 Expression of cancer/testis tumor antigens MAGE-A1, MAGE-A3/4 and NY-ESO 1 in medullary breast cancer. European Journal of Cancer, Supplement, 2009, 7, 102.	2.2	0
23	Androgen receptors: unclear ubiquitous mechanism or the missing key in the triple-negative breast cancer?. Libri Oncologici, 2020, 48, 20-26.	0.1	0
24	P-177 Overall survival of patients with left-sided metastatic colorectal cancer in real life: Experience from University Hospital for Tumors in Zagreb, Croatia. Annals of Oncology, 2020, 31, S147-S148.	1.2	0
25	110P Prognostic value of compartmental spatial analysis of tumour: Infiltrating lymphocytes in triple-negative breast cancer. Annals of Oncology, 2020, 31, S285.	1.2	0
26	Abstract PS6-56: Clinical validity of compartmental analysis of tumor-infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC) - The key is in spatial morphology?. , 2021, , .		0
27	45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial. Annals of Oncology, 2021, 32, S40.	1.2	0
28	P-16 How does reinduction of first-line chemotherapy in patients with metastatic colorectal cancer impact outcomes? Experience from the University Hospital for Tumors, Zagreb, Croatia. Annals of Oncology, 2021, 32, S101.	1.2	0
29	Abstract PD3-12: PIK3CA alterations and benefit with neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Correlative analyses of the phase III ExteNET trial. , 2018, , .		0
30	Association of tumor cells chemoresistance mechanisms and suboptimal systemic cytotoxic treatment results. Libri Oncologici, 2019, 46, 65-71.	0.1	0
31	Searching for a link between Ki-67 values and HER2 absence in 297 patients with triple-negative breast cancer.. Journal of Clinical Oncology, 2019, 37, e12551-e12551.	1.6	0
32	Phenotype variants of invasive breast cancer differ in associations between the primary tumor size and its Ki-67 value.. Journal of Clinical Oncology, 2020, 38, e12588-e12588.	1.6	0
33	Prognostic value of tumor: Infiltrating lymphocytes and androgen receptors correlation in triple negative breast cancer.. Journal of Clinical Oncology, 2020, 38, e12571-e12571.	1.6	0
34	GISTs' classifications in predicting aggressive behavior: a single institution experience. Collegium Antropologicum, 2013, 37, 977-84.	0.2	0